News of Note—Bavarian Nordic, universal flu vaccine and more

In this week's news of note, Bavarian Nordic presented more phase 2 RSV vaccine data. (Pixabay)

> Bavarian Nordic presented additional phase 2 data for its RSV candidate showing antibodies were present in participants' nasal mucosa, suggesting the vaccine can protect at the source of infection. Release

> The National Institute of Allergy and Infectious Diseases presented a strategic plan to develop a universal flu vaccine, stressing that collaboration between industry, academia and others will be important in the effort. Release

> Oxford University spinout Oxford Vacmedix raised $12.5 million to advance two cancer vaccines into human testing. Endpoints News article

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

> Sinovac has sued top shareholders over what it says was an illegal takeover attempt. Law360 article